DRG Epidemiology Intelligence
Trusted epidemiology intelligence delivering incidence, prevalence, and long range patient population forecasts to guide confident planning.
Reliable, expert curated epidemiology intelligence for confident decisions
DRG Epidemiology Intelligence delivers Trusted epidemiology intelligence designed for pharma forecasting and strategy, combining incidence and prevalence data, 10–20 year patient population forecasts, and granular segmentation across 1,000+ diseases. Built by a global team of epidemiologists using transparent, validated methods, it provides a defensible foundation for forecasting, portfolio planning, and clinical strategy.
Epidemiology you can trust and act on
Forecast with confidence, not assumptions
Get defensible epidemiology forecasts with transparent incidence and prevalence estimates and 10–20 year population projections built on transparent, expert validated models—giving teams the clarity needed to make reliable, evidence based decisions.
Granular segmentation across 1,000+ diseases
Identify patient populations with precision using advanced epidemiology segmentation across biomarkers, comorbidities, stages, age, and geography—revealing the true addressable populations behind every opportunity.
Global, consistent epidemiology at scale
Access harmonized epidemiology coverage across 170+ countries, ensuring consistency for global forecast models, portfolio planning, and cross‑market comparisons.
Deeper U.S. patient insights with Real‑World Data
Leverage U.S. claims based epidemiology to refine population estimates beyond published sources with expanded segmentation by age, gender, ethnicity, and geography. Insights sourced from Clarivate U.S. Real World Data provide national and state level granularity for more precise planning and forecasting.
Two essential tools for precise, defensible epidemiology
Expert curated epidemiology intelligence built to anchor forecasts, market sizing, and evidence based planning.
Incidence and prevalence forecasts
Access fast, reliable incidence and prevalence estimates with 10–20‑year forecasts built on transparent, expert‑validated models across 1,000+ diseases.
Epidemiology
Quickly size global markets using harmonized epidemiology across 170+ countries, including granular segmentation for rare, niche, and complex diseases.
Questions we help you answer with confidence
Epidemiology focused questions that establish the foundation for downstream market and commercial analysis.
- How large is the patient population today—and how will it change over time?
- Which subpopulations, biomarkers, or demographic groups matter most for our opportunity?
- How do incidence, prevalence, and population trends vary across global markets?
- Where do claims‑based insights reveal additional patient segments or unmet population needs?
Why Epidemiology Intelligence?
1k+
235+
40+
240+
10 or 20 year
20+ years
Frequently asked questions
Epidemiology intelligence provides structured, validated insights into disease incidence, prevalence, patient population size, and long term trends. It forms the quantitative foundation for forecasting, portfolio planning, clinical development, and market opportunity assessment.
Public datasets often lack granular segmentation, long‑range forecasting, and validated methodology. DRG Epidemiology Intelligence is built by a global team of epidemiologists, clinicians, and therapy‑area specialists using consistent models, rigorous literature review, and integrated claims‑based insights—providing a defensible, future‑focused foundation for strategic planning.
Estimates and forecasts are updated on a regular cadence to reflect new clinical evidence, disease understanding, demographic trends, and published literature. This ensures teams always have the most accurate, up‑to‑date epidemiology inputs for forecasting, portfolio planning, and strategic decision‑making.
Models draw on published literature, disease registries, government health datasets, peer‑reviewed research, and—where available—Clarivate’s U.S. Real‑World Data and backed by therapy area experts and epidemiologists. This multi‑source approach ensures forecasts reflect the best available evidence while providing clarity on assumptions, limitations, and regional differences.
Yes. Geographic and demographic segmentation helps teams identify where eligible patient populations are concentrated, which regions offer the best recruitment potential, and how population characteristics align with trial criteria—improving feasibility assessments and site‑selection decisions.
